J O'Shaughnessy Selected Research

J O'Shaughnessy Research Topics

Disease

28	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2000
8	Neoplasms (Cancer) 01/2021 - 12/2011
5	Triple Negative Breast Neoplasms 01/2022 - 08/2012
3	Disease Progression 01/2021 - 04/2015
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2018
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Cytopenia 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 01/2018
1	Alopecia (Baldness) 01/2017
1	Diarrhea 01/2017
1	Exanthema (Rash) 01/2017
1	Hyperglycemia 01/2017
1	Nausea 01/2017
1	Cardiotoxicity 10/2012
1	Hypertension (High Blood Pressure) 05/2012
1	Left Ventricular Dysfunction 05/2012
1	Proteinuria 05/2012
1	Neutropenia 06/2002
1	Hand-Foot Syndrome 02/2002
1	Enthesopathy 05/2001
1	Night Blindness (Nyctalopia) 01/2000

Drug/Important Bio-Agent (IBA)

7	Hormones (Hormone)IBA 01/2022 - 01/2018
5	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2002
3	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 10/2012
3	abemaciclibIBA 01/2022 - 12/2021
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2017
3	sacituzumab govitecanIBA 01/2021 - 12/2020
3	Letrozole (Femara)FDA LinkGeneric 11/2019 - 01/2016
3	ribociclibIBA 11/2019 - 01/2018
3	Trastuzumab (Herceptin)FDA Link 01/2019 - 12/2011
3	Bevacizumab (Avastin)FDA Link 01/2019 - 05/2012
3	Docetaxel (Taxotere)FDA Link 12/2013 - 09/2006
3	Tamoxifen FDA LinkGeneric 05/2001 - 01/2000
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2001
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2017
2	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2021
2	taxaneIBA 01/2021 - 02/2002
2	Gemcitabine FDA Link 01/2021 - 01/2018
2	Lapatinib (GW572016)FDA Link 01/2019 - 12/2011
2	Anastrozole (Arimidex)FDA LinkGeneric 01/2018 - 01/2016
2	exemestane (Aromasin)FDA Link 01/2018 - 01/2016
2	Estrogen ReceptorsIBA 11/2017 - 01/2016
2	AnthracyclinesIBA 03/2012 - 02/2002
1	veliparibIBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	Albumin-Bound Paclitaxel FDA Link 01/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021
1	B7-H1 AntigenIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	Topoisomerase InhibitorsIBA 01/2021
1	atezolizumabIBA 01/2021
1	eribulin FDA Link 01/2021
1	pembrolizumabIBA 01/2019
1	Cyclin D1IBA 01/2018
1	130-nm albumin-bound paclitaxelIBA 01/2018
1	palbociclibIBA 01/2018
1	Circulating Tumor DNAIBA 11/2017
1	NVP-BKM120IBA 01/2017
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017
1	Aromatase InhibitorsIBA 01/2016
1	Abiraterone AcetateIBA 01/2016
1	Estrogens (Estrogen)FDA Link 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 01/2016
1	HematinicsIBA 04/2015
1	Biosimilar PharmaceuticalsIBA 04/2015
1	1-dodecylpyridoxal (PLD)IBA 10/2012
1	liposomal doxorubicin (Doxil)FDA Link 10/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2012
1	Monoclonal AntibodiesIBA 05/2012
1	human ERBB2 proteinIBA 12/2011
1	Taxoids (Taxanes)IBA 09/2006
1	pegfilgrastim (Neulasta)FDA Link 06/2002
1	Filgrastim (Neupogen)FDA Link 06/2002
1	HDL CholesterolIBA 05/2001
1	Alitretinoin FDA Link 05/2001
1	Vitamin A (Retinol)FDA LinkGeneric 01/2000
1	FenretinideIBA 01/2000
1	RetinoidsIBA 01/2000
1	retinamideIBA 01/2000

Therapy/Procedure

11	Therapeutics 01/2022 - 05/2001
10	Drug Therapy (Chemotherapy) 01/2021 - 01/2000
1	Neoadjuvant Therapy 01/2022
1	Adjuvant Chemotherapy 01/2021
1	Drug Tapering 02/2002